Dennis J. Selkoe

Q: What Schools Are Affiliated With Dennis J. Selkoe

Dennis J. Selkoe is affiliated with the following schools: Washington University in St. Louis, University of California, San Diego, Vanderbilt University, University of Oklahoma, University of Virginia, Columbia University, Harvard University

Dennis J. Selkoe's AcademicInfluence.com Rankings

Dennis J. Selkoe

Medical

#96

World Rank

#156

Historical Rank

#50

USA Rank

Neurology

World Rank

#10

Historical Rank

USA Rank

medical Degrees

Download Badge

Medical

Dennis J. Selkoe's Degrees

Doctorate Medicine University of Virginia

Why Is Dennis J. Selkoe Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Dennis J. Selkoe is an American physician known for his research into the molecular basis of Alzheimer's disease. In 1985 he became Co-Director of the Center for Neurological Diseases and from 1990, Vincent and Stella Coates Professor of Neurological Diseases at Harvard Medical School. He is also a Fellow of the AAAS and a member of the National Academy of Medicine.

(See a Problem?)

Dennis J. Selkoe's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Alzheimer's disease. (2011) (15421)
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics (2002) (12550)
Alzheimer's disease: genes, proteins, and therapy. (2001) (5659)
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide (2007) (4431)
Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo (2002) (4245)
Alzheimer's Disease Is a Synaptic Failure (2002) (3930)
The amyloid hypothesis of Alzheimer's disease at 25 years (2016) (3739)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria (2014) (2513)
Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory (2008) (2379)
Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease (1996) (2328)
Aβ Oligomers – a decade of discovery (2007) (1936)
Complement and microglia mediate early synapse loss in Alzheimer mouse models (2016) (1833)
The molecular pathology of Alzheimer's disease (1991) (1825)
Amyloid β-peptide is produced by cultured cells during normal metabolism (1992) (1799)
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids (1992) (1696)
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function (2005) (1668)
Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity (1999) (1645)
Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production (1992) (1616)
Translating cell biology into therapeutic advances in Alzheimer's disease (1999) (1530)
Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway (2007) (1527)
Folding proteins in fatal ways (2003) (1332)
Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice (1997) (1324)
Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. (1986) (1291)
Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo (2003) (1226)
Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease (2004) (1183)
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation (2011) (1088)
Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease (2001) (1064)
PINK1 and Parkin Target Miro for Phosphorylation and Degradation to Arrest Mitochondrial Motility (2011) (1035)
Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior (2008) (1018)
Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons (1999) (978)
Skeletal and CNS Defects in Presenilin-1-Deficient Mice (1997) (978)
Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. (1999) (955)
Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease (1989) (901)
Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia (2009) (898)
Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. (1996) (884)
Targeting of cell-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments (1992) (877)
Immunochemical identification of the serine protease inhibitor α 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease (1988) (874)
Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases (2004) (859)
Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. (2012) (838)
Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. (2003) (831)
Alzheimer's Disease--Genotypes, Phenotype, and Treatments (1997) (829)
Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake (2009) (826)
Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration (2011) (826)
Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation* (1998) (816)
Normal and abnormal biology of the beta-amyloid precursor protein. (1994) (797)
The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease (1998) (796)
γ-Secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1, and pen-2 (2003) (781)
Alzheimer's Disease: A Central Role for Amyloid (1994) (767)
Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide (1993) (759)
Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. (1994) (732)
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. (2003) (719)
Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. (1992) (695)
Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. (2003) (692)
Amyloid β-Protein and the Genetics of Alzheimer's Disease* (1996) (684)
Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death (2003) (679)
Toward a Comprehensive Theory for Alzheimer's Disease. Hypothesis: Alzheimer's Disease Is Caused by the Cerebral Accumulation and Cytotoxicity of Amyloid β‐Protein (2000) (661)
Dopamine covalently modifies and functionally inactivates parkin (2005) (643)
Alterations in Memory Networks in Mild Cognitive Impairment and Alzheimer's Disease: An Independent Component Analysis (2006) (638)
Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. (1992) (624)
Effects of secreted oligomers of amyloid β‐protein on hippocampal synaptic plasticity: a potent role for trimers (2006) (619)
International Standard Industrial Classification of All Economic Activities (1987) (600)
The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway (1995) (580)
Sequence of Deposition of Heterogeneous Amyloid β-Peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation (1996) (571)
Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' (1998) (548)
Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. (1988) (547)
The Formation of Highly Soluble Oligomers of α-Synuclein Is Regulated by Fatty Acids and Enhanced in Parkinson's Disease (2003) (544)
Soluble Aβ Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA Receptors (2011) (538)
Clearing the Brain's Amyloid Cobwebs (2001) (538)
Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. (2000) (521)
Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. (2001) (521)
Functional Alterations in Memory Networks in Early Alzheimer’s Disease (2010) (518)
X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation. (1986) (516)
The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. (2000) (507)
The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology (1996) (501)
Neurons Regulate Extracellular Levels of Amyloid β-Protein via Proteolysis by Insulin-Degrading Enzyme (2000) (483)
beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. (1993) (477)
Resolving controversies on the path to Alzheimer's therapeutics (2011) (473)
Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. (1987) (467)
The Intracellular Domain of the β-Amyloid Precursor Protein Is Stabilized by Fe65 and Translocates to the Nucleus in a Notch-like Manner* (2001) (464)
Division for the Advancement of Women (1981) (463)
Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro. (1987) (461)
Amyloid-β oligomers: their production, toxicity and therapeutic inhibition (2001) (459)
Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. (2012) (458)
Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo (2005) (457)
Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. (1992) (456)
Block of Long-Term Potentiation by Naturally Secreted and Synthetic Amyloid β-Peptide in Hippocampal Slices Is Mediated via Activation of the Kinases c-Jun N-Terminal Kinase, Cyclin-Dependent Kinase 5, and p38 Mitogen-Activated Protein Kinase as well as Metabotropic Glutamate Receptor Type 5 (2004) (456)
Amyloid beta protein enhances the survival of hippocampal neurons in vitro. (1989) (448)
Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. (2004) (440)
Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1 (2000) (415)
Isolation of Low‐Molecular‐Weight Proteins from Amyloid Plaque Fibers in Alzheimer's Disease (1986) (414)
Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease (1993) (412)
Presenilin: Running with Scissors in the Membrane (2007) (398)
Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. (1993) (391)
Aggregation of Secreted Amyloid -Protein into Sodium Dodecyl Sulfate-stable Oligomers in Cell Culture (*) (1995) (382)
Alzheimer's disease: insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea. (1982) (381)
Protein Topology of Presenilin 1 (1996) (374)
Mutagenesis Identifies New Signals for β-Amyloid Precursor Protein Endocytosis, Turnover, and the Generation of Secreted Fragments, Including Aβ42* (1999) (372)
Clinically diagnosed Alzheimer's disease: Autopsy results in 150 cases (1988) (369)
The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. (1998) (368)
Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. (1989) (358)
Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. (1994) (350)
A Critical Function for β-Amyloid Precursor Protein in Neuronal Migration Revealed by In Utero RNA Interference (2007) (349)
The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking (2011) (339)
Nasal administration of amyloid‐β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease (2000) (337)
Soluble Aβ Inhibits Specific Signal Transduction Cascades Common to the Insulin Receptor Pathway* (2007) (337)
The Notch Ligands, Jagged and Delta, Are Sequentially Processed by α-Secretase and Presenilin/γ-Secretase and Release Signaling Fragments* (2003) (335)
Amyloid β-protein deposition in tissues other than brain in Alzheimer's disease (1989) (332)
Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. (1994) (329)
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. (2002) (325)
The Proteolytic Fragments of the Alzheimer’s Disease-associated Presenilin-1 Form Heterodimers and Occur as a 100–150-kDa Molecular Mass Complex* (1998) (321)
Activity-dependent isolation of the presenilin– γ-secretase complex reveals nicastrin and a γ substrate (2002) (320)
Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization (2008) (320)
Amyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma* (1996) (312)
Alzheimer's disease: genotypes, phenotypes, and treatments. (1997) (311)
Enhanced Production and Oligomerization of the 42-residue Amyloid β-Protein by Chinese Hamster Ovary Cells Stably Expressing Mutant Presenilins* (1997) (310)
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. (2003) (310)
Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. (1996) (306)
Amyloid β-Protein Is Degraded by Cellular Angiotensin-converting Enzyme (ACE) and Elevated by an ACE Inhibitor* (2005) (304)
Deciphering the genetic basis of Alzheimer's disease. (2002) (303)
Presenilin Proteins Undergo Heterogeneous Endoproteolysis between Thr291and Ala299and Occur as Stable N- and C-Terminal Fragments in Normal and Alzheimer Brain Tissue (1997) (301)
Peptidomimetic probes and molecular modeling suggest that Alzheimer's gamma-secretase is an intramembrane-cleaving aspartyl protease. (1999) (301)
The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. (2014) (300)
Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. (2009) (297)
α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins (2001) (293)
β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease (2017) (285)
Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. (2002) (272)
The origins of Alzheimer disease: a is for amyloid. (2000) (271)
Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. (1993) (268)
Inflammation and therapeutic vaccination in CNS diseases (2002) (264)
Biochemistry of altered brain proteins in Alzheimer's disease. (1989) (261)
The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. (2010) (259)
Certain Inhibitors of Synthetic Amyloid β-Peptide (Aβ) Fibrillogenesis Block Oligomerization of Natural Aβ and Thereby Rescue Long-Term Potentiation (2005) (259)
Calcium ionophore increases amyloid beta peptide production by cultured cells. (1994) (258)
Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer disease. (1997) (256)
Cell Surface Presenilin-1 Participates in the γ-Secretase-like Proteolysis of Notch* (1999) (254)
Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. (2005) (251)
Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid beta-protein. (1992) (246)
Antibodies to paired helical filaments in Alzheimer's disease do not recognize normal brain proteins (1983) (245)
Direct and Potent Regulation of γ-Secretase by Its Lipid Microenvironment* (2008) (244)
Alzheimer Disease: Mechanistic Understanding Predicts Novel Therapies (2004) (241)
Generation of amyloid β protein from its precursor is sequence specific (1995) (240)
The Transmembrane Aspartates in Presenilin 1 and 2 Are Obligatory for γ-Secretase Activity and Amyloid β-Protein Generation* (2000) (236)
The Role of APP Processing and Trafficking Pathways in the Formation of Amyloid β‐Protein a (1996) (236)
Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation (2015) (233)
Accumulation of Phosphorylated Neurofilaments in Anterior Horn Motoneurons of Amyotrophic Lateral Sclerosis Patients (1988) (233)
The Alzheimer’s Disease-Associated Presenilins Are Differentially Phosphorylated Proteins Located Predominantly within the Endoplasmic Reticulum (1996) (231)
A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration (2016) (229)
Intraneuronal Aβ42 accumulation in Down syndrome brain (2002) (227)
Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. (2002) (226)
Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. (2004) (225)
Assembly of the γ-Secretase Complex Involves Early Formation of an Intermediate Subcomplex of Aph-1 and Nicastrin* (2003) (225)
A Seed for Alzheimer Amyloid in the Brain (2004) (223)
The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. (2005) (223)
Trafficking of cell surface beta-amyloid precursor protein: retrograde and transcytotic transport in cultured neurons (1995) (223)
Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate (2017) (222)
Microtubule-associated protein 2: monoclonal antibodies demonstrate the selective incorporation of certain epitopes into Alzheimer neurofibrillary tangles. (1984) (222)
Preventing Alzheimer’s Disease (2012) (221)
Purification and characterization of the human gamma-secretase complex. (2004) (216)
The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid. (1989) (216)
Homology of the amyloid beta protein precursor in monkey and human supports a primate model for beta amyloidosis in Alzheimer's disease. (1991) (214)
A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. (2009) (211)
The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. (2003) (211)
Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. (1999) (211)
Trafficking of cell-surface amyloid beta-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody. (1996) (210)
Brain transglutaminase: in vitro crosslinking of human neurofilament proteins into insoluble polymers. (1982) (210)
Soluble, Prefibrillar α-Synuclein Oligomers Promote Complex I-dependent, Ca2+-induced Mitochondrial Dysfunction* (2014) (208)
Presenilin, Notch, and the genesis and treatment of Alzheimer's disease (2001) (207)
A Substrate-Based Difluoro Ketone Selectively Inhibits Alzheimer's γ-Secretase Activity (1998) (205)
Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease. (1999) (204)
Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. (2011) (201)
In Vivo Cross-linking Reveals Principally Oligomeric Forms of α-Synuclein and β-Synuclein in Neurons and Non-neural Cells* (2013) (200)
Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1 (2008) (200)
Amyloid protein and Alzheimer's disease. (1991) (199)
Alzheimer's Disease Aβ Vaccine Reduces Central Nervous System Aβ Levels in a Non-Human Primate, the Caribbean Vervet (2004) (198)
Expression of Alzheimer’s Disease-associated Presenilin-1 Is Controlled by Proteolytic Degradation and Complex Formation* (1998) (197)
Microtubule-associated protein tau (? ) is a major antigenic component of paired helical filaments in Alzheimer disease (1987) (197)
Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's (2016) (196)
Cytosolic Phospholipase A2(cPLA2) Immunoreactivity Is Elevated in Alzheimer's Disease Brain (1996) (196)
Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. (2012) (196)
Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. (1998) (192)
Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer's disease. An immunoelectron microscopic study. (1992) (191)
Amyloid beta-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth. (1993) (187)
Orally available compound prevents deficits in memory caused by the Alzheimer amyloid‐β oligomers (2006) (186)
Recognition of Alzheimer paired helical filaments by monoclonal neurofilament antibodies is due to crossreaction with tau protein. (1987) (186)
Degradation of Amyloid β-Protein by a Metalloprotease Secreted by Microglia and Other Neural and Non-neural Cells* (1997) (183)
Increased expression of beta-amyloid precursor protein during neuronal differentiation is not accompanied by secretory cleavage. (1992) (181)
Alzheimer disease: mechanistic understanding predicts novel therapies. (2004) (180)
Identification of β-Secretase (BACE1) Substrates Using Quantitative Proteomics (2009) (179)
Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi. (1998) (176)
The Seminal Role of β‐Amyloid in the Pathogenesis of Alzheimer Disease (1992) (175)
Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. (2006) (174)
Gene dosage of the amyloid beta precursor protein in Alzheimer's disease. (1987) (173)
Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. (2011) (172)
Protein chemical and immunocytochemical studies of meningovascular β-amyloid protein in Alzheimer's disease and normal aging (1988) (171)
γ-Secretase Exists on the Plasma Membrane as an Intact Complex That Accepts Substrates and Effects Intramembrane Cleavage* (2005) (170)
Defining molecular targets to prevent Alzheimer disease. (2005) (168)
Deciphering Alzheimer disease. (2012) (168)
Rio Declaration on Environment and Development (1992) (166)
Soluble Aβ Oligomers Are Rapidly Sequestered from Brain ISF In Vivo and Bind GM1 Ganglioside on Cellular Membranes (2014) (165)
Secreted beta-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation. (1994) (164)
Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease (2001) (164)
Title Amyloid β-protein fibrillogenesis . Structure and biological activity of protofibrillar intermediates (1999) (162)
Proteomic Profiling of γ-Secretase Substrates and Mapping of Substrate Requirements (2008) (161)
Environmental Novelty Activates β2-Adrenergic Signaling to Prevent the Impairment of Hippocampal LTP by Aβ Oligomers (2013) (160)
The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins. (2000) (158)
Selective ectodomain phosphorylation and regulated cleavage of beta‐amyloid precursor protein. (1994) (157)
Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. (2000) (152)
Alzheimer disease in 2020. (2012) (151)
Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. (2007) (150)
Lipidomic Analysis of α-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment. (2018) (150)
Subcellular Distribution and Turnover of Presenilins in Transfected Cells* (1998) (148)
α‐Synuclein and Polyunsaturated Fatty Acids Promote Clathrin‐Mediated Endocytosis and Synaptic Vesicle Recycling (2009) (148)
Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. (2004) (148)
Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1. (2008) (147)
Trafficking of cell-surface amyloid beta-protein precursor. II. Endocytosis, recycling and lysosomal targeting detected by immunolocalization. (1996) (143)
Altered Fatty Acid Composition of Dopaminergic Neurons Expressing α-Synuclein and Human Brains with α-Synucleinopathies* (2003) (143)
The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. (1996) (141)
Deciphering Alzheimer's disease: the amyloid precursor protein yields new clues. (1990) (138)
Neurofibrillary Tangles and Senile Plaques in Aged Bears (1988) (138)
Presenilin complexes with the C-terminal fragments of amyloid precursor protein at the sites of amyloid beta-protein generation. (2000) (138)
Identification of a stable fragment of the Alzheimer amyloid precursor containing the beta-protein in brain microvessels. (1992) (138)
Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. (1994) (137)
Polarized sorting of beta-amyloid precursor protein and its proteolytic products in MDCK cells is regulated by two independent signals (1995) (136)
Detergent-dependent dissociation of active gamma-secretase reveals an interaction between Pen-2 and PS1-NTF and offers a model for subunit organization within the complex. (2004) (136)
Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. (2000) (133)
Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice (2003) (133)
Alzheimer disease and aducanumab: adjusting our approach (2019) (132)
Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. (2005) (131)
Amyloid β protein precursor and the pathogenesis of Alzheimer's disease (1989) (130)
Heparin-binding properties of the amyloidogenic peptides Abeta and amylin. Dependence on aggregation state and inhibition by Congo red. (1997) (130)
Cell Surface Amyloid β-Protein Precursor Colocalizes with β1 Integrins at Substrate Contact Sites in Neural Cells (1997) (130)
KTKEGV repeat motifs are key mediators of normal α-synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity (2015) (130)
N-Alpha-Acetylation of α-Synuclein Increases Its Helical Folding Propensity, GM1 Binding Specificity and Resistance to Aggregation (2014) (129)
The “Nonamyloidogenic” p3 Fragment (Amyloid β17-42) Is a Major Constituent of Down's Syndrome Cerebellar Preamyloid* (1996) (128)
Intraneuronal Abeta42 accumulation in Down syndrome brain. (2002) (128)
The APP family of proteins: similarities and differences. (2007) (127)
Diffuse plaques contain C-terminal Aβ 42 and not Aβ 40: Evidence from cats and dogs (1996) (127)
C-Terminally Truncated Forms of Tau, But Not Full-Length Tau or Its C-Terminal Fragments, Are Released from Neurons Independently of Cell Death (2015) (125)
Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts (2017) (122)
Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. (2004) (122)
Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease. (2008) (122)
Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Aβ assembly forms throughout life (2009) (121)
Reducing Amyloid Plaque Burden via Ex Vivo Gene Delivery of an Aβ-Degrading Protease: A Novel Therapeutic Approach to Alzheimer Disease (2007) (120)
Aspartate Mutations in Presenilin and γ‐Secretase Inhibitors Both Impair Notch1 Proteolysis and Nuclear Translocation with Relative Preservation of Notch1 Signaling (2000) (120)
Inhibition of Receptor-mediated Endocytosis Demonstrates Generation of Amyloid β-Protein at the Cell Surface* (2003) (119)
Detection of Aggregation-Competent Tau in Neuron-Derived Extracellular Vesicles (2018) (119)
A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer’s brain (2020) (118)
Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution. (2009) (118)
gamma-Secretase cleavage and binding to FE65 regulate the nuclear translocation of the intracellular C-terminal domain (ICD) of the APP family of proteins. (2003) (117)
Physiological Regulation of the β-Amyloid Precursor Protein Signaling Domain by c-Jun N-Terminal Kinase JNK3 during Neuronal Differentiation (2005) (117)
Normal Cellular Processing of the β‐Amyloid Precursor Protein Results in the Secretion of the Amyloid β Peptide and Related Molecules a (1993) (116)
Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate. (2002) (116)
A de novo designed helix-turn-helix peptide forms nontoxic amyloid fibrils (2000) (116)
Proteolytic processing of the Alzheimer disease-associated presenilin-1 generates an in vivo substrate for protein kinase C. (1997) (115)
Tau antisera recognize neurofibrillary tangles in a range of neurodegenerative disorders (1987) (115)
Soluble Arctic amyloid β protein inhibits hippocampal long‐term potentiation in vivo (2004) (114)
The lysosomal cysteine protease, cathepsin S, is increased in Alzheimer's disease and Down syndrome brain. An immunocytochemical study. (1995) (114)
Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease (2007) (114)
Nicastrin functions to sterically hinder γ-secretase–substrate interactions driven by substrate transmembrane domain (2015) (114)
Biochemical and immunological characterization of neurofilaments in experimental neurofibrillary degeneration induced by aluminum (1979) (113)
In vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692-->Gly) Alzheimer's disease. (2001) (113)
Passage of human amyloid β-protein 1–40 across the murine blood-brain barrier (1994) (112)
Complex N-linked Glycosylated Nicastrin Associates with Active γ-Secretase and Undergoes Tight Cellular Regulation* (2002) (110)
Dynamic Analysis of Amyloid β-Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal Aβ during Age-Related Plaque Formation (2011) (110)
Effects of membrane lipids on the activity and processivity of purified γ-secretase. (2012) (110)
Aging brain, aging mind. (1992) (109)
Notch and the amyloid precursor protein are cleaved by similar gamma-secretase(s). (2003) (107)
γ-Secretase Substrate Selectivity Can Be Modulated Directly via Interaction with a Nucleotide-binding Site* (2005) (107)
New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF (2013) (107)
The therapeutics of Alzheimer's disease: Where we stand and where we are heading (2013) (107)
Neurofibrillary degeneration of cholinergic and noncholinergic neurons of the basal forebrain in Alzheimer's disease (1986) (105)
Kinetics of Amyloid β-Protein Degradation Determined by Novel Fluorescence- and Fluorescence Polarization-based Assays* (2003) (103)
Amyloid beta-protein deposition in tissues other than brain in Alzheimer's disease. (1989) (103)
Additive Effects of PS1 and APP Mutations on Secretion of the 42-Residue Amyloid β-Protein (1998) (101)
Nasal Aβ Treatment Induces Anti‐Aβ Antibody Production and Decreases Cerebral Amyloid Burden in PD‐APP Mice (2000) (100)
Biochemical and Functional Interaction of Disrupted-in-Schizophrenia 1 and Amyloid Precursor Protein Regulates Neuronal Migration during Mammalian Cortical Development (2010) (99)
Genomic DISC1 Disruption in hiPSCs Alters Wnt Signaling and Neural Cell Fate. (2015) (99)
Aging, Amyloid, and Alzheimer's Disease: A Perspective in Honor of Carl Cotman (2003) (99)
miR-212 and miR-132 Are Downregulated in Neurally Derived Plasma Exosomes of Alzheimer’s Patients (2019) (99)
LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-β peptide in a blood–brain barrier in vitro model (2008) (98)
Designed Inhibitors of Insulin-Degrading Enzyme Regulate the Catabolism and Activity of Insulin (2010) (97)
Tau Epitopes are Incorporated into a Range of Lesions in Alzheimer's Disease (1987) (97)
Functional γ-secretase complex assembly in Golgi/trans-Golgi network: interactions among presenilin, nicastrin, Aph1, Pen-2, and γ-secretase substrates (2003) (97)
The Vacuolar H-ATPase Inhibitor Bafilomycin A1 Differentially Affects Proteolytic Processing of Mutant and Wild-type -Amyloid Precursor Protein (*) (1995) (97)
Molecular pathology of amyloidogenic proteins and the role of vascular amyloidosis in Alzheimer's disease (1989) (95)
The amyloid-beta forming tripeptide cleavage mechanism of γ-secretase (2016) (93)
Cell surface presenilin-1 participates in the gamma-secretase-like proteolysis of Notch. (1999) (92)
MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways (2018) (91)
Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. (1993) (91)
Immunostaining of neurofibrillary tangles in Alzheimer's senile dementia with a neurofilament antiserum (1982) (91)
Altered structural proteins in plaques and tangles: What do they tell us about the biology of Alzheimer's disease? (1986) (90)
Ectodomain Phosphorylation of β-Amyloid Precursor Protein at Two Distinct Cellular Locations* (1997) (90)
Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease (2018) (90)
Amyloid β-protein precursor: new clues to the genesis of Alzheimer's disease (1994) (90)
Polarized secretion of beta-amyloid precursor protein and amyloid beta-peptide in MDCK cells. (1994) (90)
The monoclonal antibody, Alz 50, recognizes tau proteins in Alzheimer's disease brain (1988) (88)
Secreted Amyloid β-Proteins in a Cell Culture Model Include N-Terminally Extended Peptides That Impair Synaptic Plasticity (2014) (88)
Inhibition of Amyloid β-Protein Production in Neural Cells by the Serine Protease Inhibitor AEBSF (1996) (88)
Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. (2003) (88)
Degradation of Amyloid -Protein by a Serine Protease--Macroglobulin Complex (*) (1996) (88)
Generation of amyloid beta protein from its precursor is sequence specific. (1995) (87)
Imaging Alzheimer's amyloid (2000) (86)
Decreased Catalytic Activity of the Insulin-degrading Enzyme in Chromosome 10-Linked Alzheimer Disease Families* (2007) (86)
Antibodies to non-beta regions of the beta-amyloid precursor protein detect a subset of senile plaques. (1991) (84)
A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid (2015) (84)
Aβ oligomers inhibit synapse remodelling necessary for memory consolidation (2011) (84)
Lipidomic profiling in mouse brain reveals differences between ages and genders, with smaller changes associated with α‐synuclein genotype (2009) (84)
Lysosomal processing of amyloid precursor protein to A beta peptides: a distinct role for cathepsin S. (1995) (84)
Polyunsaturated Fatty Acids Induce α-Synuclein-Related Pathogenic Changes in Neuronal Cells (2007) (84)
Environmental Enrichment Potently Prevents Microglia-Mediated Neuroinflammation by Human Amyloid β-Protein Oligomers (2016) (83)
Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. (2005) (83)
Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization. (2000) (82)
Amyloid beta dimers/trimers potently induce cofilin-actin rods that are inhibited by maintaining cofilin-phosphorylation (2011) (82)
Aggregation and catabolism of disease-associated intra-Aβ mutations: reduced proteolysis of AβA21G by neprilysin (2008) (82)
Receptor-Mediated Transport of Human Amyloid β-Protein 1–40 and 1–42 at the Blood–Brain Barrier (1999) (81)
The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation. (2000) (80)
Adult onset Hallervorden-Spatz disease with neurofibrillary pathology. A discrete clinicopathological entity. (1987) (80)
Small non-fibrillar assemblies of amyloid β-protein bearing the Arctic mutation induce rapid neuritic degeneration (2005) (80)
Plasma amyloid-beta as a predictor of dementia and cognitive decline: A systematic review and meta-analysis (2011) (80)
Nasal Vaccination with β-Amyloid Peptide for the Treatment of Alzheimer's Disease (2001) (80)
Protofibrils of amyloid β-protein inhibit specific K+ currents in neocortical cultures (2003) (79)
New insights into cellular α-synuclein homeostasis in health and disease (2016) (78)
Purification of α-Synuclein from Human Brain Reveals an Instability of Endogenous Multimers as the Protein Approaches Purity (2014) (76)
Amyloid β-protein induced electrophysiological changes are dependent on aggregation state: N-methyl-d-aspartate (NMDA) versus non-NMDA receptor/channel activation (2004) (76)
Notch and presenilins in vertebrates and invertebrates: implications for neuronal development and degeneration (2000) (75)
Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease (2018) (74)
Antisera to an amino-terminal peptide detect the amyloid protein precursor of Alzheimer's disease and recognize senile plaques. (1988) (72)
Detection of soluble forms of the β-amyloid precursor protein in human plasma (1990) (72)
Microinjection of synthetic amyloid beta-protein in monkey cerebral cortex fails to produce acute neurotoxicity. (1993) (72)
Small-Molecule Activators of Insulin-Degrading Enzyme Discovered through High-Throughput Compound Screening (2009) (71)
Caffeine Stimulates Amyloid β‐Peptide Release from β‐Amyloid Precursor Protein‐Transfected HEK293 Cells (1997) (71)
Amyloid β-protein and beyond: the path forward in Alzheimer’s disease (2020) (71)
Identification of amyloid beta protein in the brain of the small, short-lived Lemurian primate Microcebus murinus (1994) (71)
The deposition of amyloid proteins in the aging mammalian brain: implications for Alzheimer's disease. (1989) (70)
Beta APP mRNA transcription is increased in cultured fibroblasts from the familial Alzheimer's disease-1 family. (1995) (68)
Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules. (1993) (67)
Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. (2003) (67)
Cell biology of the beta-amyloid precursor protein and the genetics of Alzheimer's disease. (1996) (67)
Isolation of hamster brain astroglia by in vitro cultivation and subcutaneous growth, and content of cerebroside, ganglioside, RNA and DNA. (1970) (66)
α1-Antichymotrypsin is present together with the β-protein in monkey brain amyloid deposits (1989) (66)
Regulation of rat magnocellular neurosecretory system by D-aspartate: evidence for biological role(s) of a naturally occurring free D-amino acid in mammals. (2000) (66)
Huntington's disease: Changes in striatal proteins reflect astrocytic gliosis (1982) (65)
Alzheimer's disease: Immunoreactivity of neurofibrillary tangles with anti-neurofilament and anti-paired helical filament antibodies (1984) (65)
The anterior tarsal tunnel syndrome. Report of two cases. (1981) (65)
Toward structural elucidation of the gamma-secretase complex. (2009) (65)
In search of γ-secretase: Presenilin at the cutting edge (2000) (64)
Unrecognized vitamin D3 deficiency is common in Parkinson disease (2013) (64)
Nomenclature of amyloid fibril proteins. Report from the meeting of the International Nomenclature Committee on Amyloidosis, August 8-9, 1998. Part 1. (1999) (63)
Synthetic amyloid β-protein fails to produce specific neurotoxicity in monkey cerebral cortex (1992) (61)
Detection of distinct isoform patterns of the β-amyloid precursor protein in human platelets and lymphocytes (1992) (61)
Loss of native &agr;-synuclein multimerization by strategically mutating its amphipathic helix causes abnormal vesicle interactions in neuronal cells (2017) (61)
Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. (2015) (60)
Impaired glutamate recycling and GluN2B‐mediated neuronal calcium overload in mice lacking TGF‐β1 in the CNS (2013) (60)
Presenilin‐1 Exists in Both Pre‐ and Post‐Golgi Compartments and Recycles Via COPI‐Coated Membranes (2003) (59)
Novel neuritic clusters with accumulations of amyloid precursor protein and amyloid precursor-like protein 2 immunoreactivity in brain regions damaged by thiamine deficiency. (1996) (59)
A mathematical model of the impact of novel treatments on the Aβ burden in the Alzheimer’s brain, CSF and plasma (2015) (59)
Identification of neurotoxic cross-linked amyloid-β dimers in the Alzheimer's brain. (2019) (59)
Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein. (1999) (58)
Permeability and Residual Plasma Volume of Human, Dutch Variant, and Rat Amyloid β-Protein 1-40 at the Blood–Brain Barrier (1997) (58)
Parkinson’s disease: proteinopathy or lipidopathy? (2020) (58)
Cell-type Dependent Alzheimer's Disease Phenotypes: Probing the Biology of Selective Neuronal Vulnerability (2017) (58)
Difluoro ketone peptidomimetics suggest a large S1 pocket for Alzheimer's gamma-secretase: implications for inhibitor design. (2000) (57)
The ups and downs of Aβ (2006) (57)
Depression is associated with low plasma Aβ42 independently of cardiovascular disease in the homebound elderly (2007) (56)
Transforming growth factor-beta bound to soluble derivatives of the beta amyloid precursor protein of Alzheimer's disease. (1990) (56)
Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea racemosa. (2012) (56)
Molecular basis for the thiol sensitivity of insulin-degrading enzyme (2008) (56)
Intramembrane Proteases--Mixing Oil and Water (2002) (55)
Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells. (2007) (55)
Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid (2019) (55)
Ten-year change in plasma amyloid beta levels and late-life cognitive decline. (2009) (55)
α‐Synuclein Neuropathology is Controlled by Nuclear Hormone Receptors and Enhanced by Docosahexaenoic Acid in A Mouse Model for Parkinson's Disease (2012) (55)
Functional gamma-secretase complex assembly in Golgi/trans-Golgi network: interactions among presenilin, nicastrin, Aph1, Pen-2, and gamma-secretase substrates. (2003) (55)
Pancortins interact with amyloid precursor protein and modulate cortical cell migration (2012) (53)
Early network dysfunction in Alzheimer's disease (2019) (53)
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease (2012) (52)
Parkinson’s disease: proteinopathy or lipidopathy? (2020) (51)
Alzheimer's disease: A technical KO of amyloid-β peptide (1998) (50)
Treatments for Alzheimer's disease emerge (2021) (50)
Developing preventive therapies for chronic diseases: lessons learned from Alzheimer's disease. (2007) (50)
Systematic evaluation of candidate ligands regulating ectodomain shedding of the amyloid precursor protein (2013) (50)
Physical and functional interaction between the α- and γ-secretases: A new model of regulated intramembrane proteolysis (2015) (50)
HLA-DR Alleles in Amyloid β-Peptide Autoimmunity: A Highly Immunogenic Role for the DRB1*1501 Allele1 (2009) (49)
Isolation of low-n amyloid β-protein oligomers from cultured cells, CSF, and brain. (2011) (49)
Diffuse plaques contain C-terminal A beta 42 and not A beta 40: evidence from cats and dogs. (1996) (49)
A substrate-based difluoro ketone selectively inhibits Alzheimer's gamma-secretase activity. (1998) (48)
Naturally occurring free D-aspartate is a nuclear component of cells in the mammalian hypothalamo-neurohypophyseal system (2002) (47)
In the beginning ... (1991) (47)
SnapShot: Pathobiology of Alzheimer's Disease (2013) (47)
Co-expression of β-amyloid precursor protein (βAPP) and apolipoprotein E in cell culture: analysis of βAPP processing (1995) (47)
A cellular complex of BACE1 and γ-secretase sequentially generates Aβ from its full-length precursor (2019) (46)
FAD Mutations in Presenilin-1 or Amyloid Precursor Protein Decrease the Efficacy of a γ-Secretase Inhibitor: Evidence for Direct Involvement of PS1 in the γ-Secretase Cleavage Complex (2000) (46)
Cell models of lipid-rich α-synuclein aggregation validate known modifiers of α-synuclein biology and identify stearoyl-CoA desaturase (2019) (46)
Rapid purification of active γ‐secretase, an intramembrane protease implicated in Alzheimer’s disease (2007) (45)
Amyloid beta-protein precursor: new clues to the genesis of Alzheimer's disease. (1994) (45)
An in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimer’s disease (2018) (45)
Amino-terminal region of the β-amyloid precursor protein activates mitogen-activated protein kinase (1995) (44)
Enriched environment enhances β‐adrenergic signaling to prevent microglia inflammation by amyloid‐β (2018) (44)
The seminal role of beta-amyloid in the pathogenesis of Alzheimer disease. (1992) (44)
Amyloid β-Protein Fibrillogenesis (1999) (44)
Aph-1 Associates Directly with Full-length and C-terminal Fragments of γ-Secretase Substrates* (2010) (43)
A cDNA for a human microtubule associated protein 2 epitope in the Alzheimer neurofibrillary tangle. (1986) (43)
Crucial Roles for SIRT2 and AMPA Receptor Acetylation in Synaptic Plasticity and Memory. (2017) (42)
Deciphering Alzheimer's disease: the pace quickens (1987) (42)
A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations (2017) (42)
Stem cell-derived neurons reflect features of protein networks, neuropathology, and cognitive outcome of their aged human donors (2021) (40)
Systematic analysis of time-dependent neural effects of soluble amyloid β oligomers in culture and in vivo: Prevention by scyllo-inositol (2015) (40)
Caffeine stimulates amyloid beta-peptide release from beta-amyloid precursor protein-transfected HEK293 cells. (1997) (39)
Amyloid beta protein precursor and the pathogenesis of Alzheimer's disease. (1989) (39)
How do Soluble Oligomers of Amyloid β-protein Impair Hippocampal Synaptic Plasticity? (2010) (39)
Aging, amyloid, and Alzheimer's disease. (1989) (39)
Enhancer function and novel DNA binding protein activity in the near upstream betaAPP gene promoter. (1999) (38)
The Future of Anti-Amyloid Trials (2019) (37)
Rapid Notch1 Nuclear Translocation after Ligand Binding Depends on Presenilin‐associated γ‐Secretase Activity (2000) (37)
Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. (2000) (37)
Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. (2001) (37)
Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer’s disease (2018) (37)
INVESTIGATION OF SILICON AND ALUMINUM CONTENT IN ISOLATED SENILE PLAQUE CORES BY LASER MICROPROBE MASS ANALYSIS (LAMMA) (1986) (37)
Potential human transmission of amyloid β pathology: surveillance and risks (2020) (35)
Amyloid-lowering isocoumarins are not direct inhibitors of γ-secretase (2002) (35)
Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex. (1996) (35)
Amyloid beta-peptide is produced by cultured cells during normal metabolism: a reprise. (2006) (35)
Recognition of Alzheimer paired helical filaments by monoclonal neurofilament antibodies is due to cross-reaction with tau protein (1987) (34)
Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview (2011) (34)
Defining the Native State of α-Synuclein (2013) (34)
A New Method for Quantitative Immunoblotting of Endogenous α-Synuclein (2013) (34)
Effects of neurotoxic industrial solvents on cultured neuroblastoma cells: methyl n-butyl ketone, n-hexane and derivatives. (1978) (32)
Cholinergic Function in Lumbar Aluminum Myelopathy (1983) (32)
Altered protein composition of isolated human cortical neurons in alzheimer disease (1980) (31)
Indirect Techniques for Demographic Estimation (1982) (31)
Evidence that alpha-synuclein does not inhibit phospholipase D. (2009) (31)
Images in neuroscience. Alzheimer's disease: from genes to pathogenesis. (1997) (31)
β‐Secretase cleavage is not required for generation of the intracellular C‐terminal domain of the amyloid precursor family of proteins (2010) (30)
Alzheimer's Disease Is the Most Common Neurodegenerative Disorder (1999) (30)
The ups and downs of Abeta. (2006) (29)
In search of gamma-secretase: presenilin at the cutting edge. (2000) (29)
Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals (2020) (28)
A CHARACTERISTIC BINDING AFFINITY BETWEEN HEPARAN SULFATE PROTEOGLYCANS AND THE A4 AMYLOID PROTEIN OF ALZHEIMERʼS DISEASE: 154 (1989) (28)
Performance characteristics of plasma amyloid-beta 40 and 42 assays. (2009) (28)
Electron Microscopic Localization of Alzheimer Neurofibrillary Tangle Components Recognized by an Antiserum to Paired Helical Filaments (1986) (28)
FAD mutations in presenilin-1 or amyloid precursor protein decrease the efficacy of a gamma-secretase inhibitor: evidence for direct involvement of PS1 in the gamma-secretase cleavage complex. (2000) (27)
A Stearoyl–Coenzyme A Desaturase Inhibitor Prevents Multiple Parkinson Disease Phenotypes in α‐Synuclein Mice (2020) (27)
beta-Amyloid, protein processing and Alzheimer's disease. (1995) (27)
Proteolysis of Chimeric β-Amyloid Precursor Proteins Containing the Notch Transmembrane Domain Yields Amyloid β-like Peptides* (2002) (27)
Presenilin‐1‐mediated Retention of APP Derivatives in Early Biosynthetic Compartments (2006) (26)
Alzheimer's disease: exposure of neurofilament immunoreactivity in SDS-insoluble paired helical filaments (1984) (26)
Association of SNCA with Parkinson: Replication in the Harvard NeuroDiscovery Center Biomarker Study (2011) (26)
Neurologic and Cardiovascular Effects of Hypotension in the Monkey (1979) (26)
Familial hyperprolinemia and mental retardation (1969) (25)
Co-expression of beta-amyloid precursor protein (betaAPP) and apolipoprotein E in cell culture: analysis of betaAPP processing. (1995) (25)
Myelin basic protein in Alzheimer disease neuronal fractions and mammalian neurofilament preparations (1981) (25)
Passage of human amyloid beta-protein 1-40 across the murine blood-brain barrier. (1994) (25)
Corrigendum: Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation (2015) (25)
Structural biology: Enzyme target to latch on to (2006) (25)
Antibodies to amyloid β protein (Aβ) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1996) (24)
Molecular pathology of the aging human brain (1982) (24)
Isolation of paired helical filaments and amyloid fibers from human brain. (1986) (24)
Production of amyloid-β-peptide by cultured cells: No evidence for internal initiation of translation at Met596 (1993) (24)
Presenilins, β-amyloid precursor protein and the molecular basis of Alzheimer's disease (2001) (23)
A profile of impaired insulin degradation in relation to late‐life cognitive decline: A preliminary investigation (2009) (23)
[Biochemistry of Alzheimer's disease]. (1990) (22)
Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes (2008) (22)
Pen-2 Is Essential for γ-Secretase Complex Stability and Trafficking but Partially Dispensable for Endoproteolysis (2014) (22)
Missense on the membrane (1995) (22)
THE β AMYLOID PROTEIN PRECURSOR OF ALZHEIMERʼS DISEASE HAS SOLUBLE DERIVATIVES FOUND IN HUMAN BRAIN AND CEREBROSPINAL FLUID: 231 (1989) (22)
Aducanumab: Appropriate Use Recommendations Update (2022) (22)
If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline? (2022) (22)
Vesicle trafficking and lipid metabolism in synucleinopathy (2020) (21)
α-1-Antichymotrypsin, a Serine Protease Inhibitor, is a Component of the Amyloid Deposits in Alzheimer’s Disease (1988) (21)
Biochemistry. Intramembrane proteases--mixing oil and water. (2002) (20)
Hyperpathia and sensory level due to parietal lobe arteriovenous malformation. (1981) (20)
Heparin-binding Properties of the Amyloidogenic Peptides Aβ and Amylin (1997) (20)
γ-secretase processing of APLP1 leads to the production of a p3-like peptide that does not aggregate and is not toxic to neurons (2009) (19)
Cryo-Electron Microscopy Structure of Purified γ-Secretase at 12 Å Resolution (2008) (19)
Analysis of α-synuclein species enriched from cerebral cortex of humans with sporadic dementia with Lewy bodies (2020) (19)
The Many Faces of A: Structures and Activity (2003) (19)
Toward a remembrance of things past: deciphering Alzheimer disease. (2003) (18)
Axonal transport of cytoskeletal proteins in aluminum toxicity. Aluminum toxicity and axonal transport. (1983) (18)
Characterization of Postmortem Human Brain Proteins by Two‐Dimensional Gel Electrophoresis (1982) (18)
Peroxisome proliferator-activated receptor gamma enhances the activity of an insulin degrading enzyme-like metalloprotease for amyloid-beta clearance. (2010) (18)
Gamma-secretase as a target for Alzheimer's disease therapy: Small-molecule development (2013) (17)
Toward the Characterization and Identification of γ‐Secretases Using Transition‐state Analogue Inhibitors (2000) (17)
Response to: Pardossi-Piquard et al., “Presenilin-Dependent Transcriptional Control of the Aβ-Degrading Enzyme Neprilysin by Intracellular Domains of βAPP and APLP.” Neuron 46, 541–554 (2007) (16)
Alzheimer ’ s disease results from the cerebral accumulation and cytotoxicity of amyloid β-protein A reanalysis of a therapeutic hypothesis Dedicated to the memory of (2001) (16)
Multiple BACE1 inhibitors abnormally increase the BACE1 protein level in neurons by prolonging its half-life (2019) (16)
Hydrophilic loop 1 of Presenilin-1 and the APP GxxxG transmembrane motif regulate γ-secretase function in generating Alzheimer-causing Aβ peptides (2021) (15)
Amyloid protein in Alzheimer's disease. (1989) (15)
MINIREVIEW: Amyloid Protein in Alzheimer's Disease (1989) (15)
Biochemistry of Alzheimer's and Prion Diseases (1999) (15)
Alzheimer’s Disease: Lessons from Cell Biology (2011) (15)
Altered structural proteins in plaques and tangles: What do they tell us about the biology of Alzheimer??s disease? (1987) (14)
An ultra‐sensitive immunoassay detects and quantifies soluble Aβ oligomers in human plasma (2021) (14)
Genetic deletion of the GATA1‐regulated protein α‐synuclein reduces oxidative stress and nitric oxide synthase levels in mature erythrocytes (2014) (14)
Pure motor hemiplegia secondary to brain-stem tumour. (1975) (14)
The biology of Alzheimer disease (2012) (14)
Immunostaining of neurofibrillary tangles in Alzheimerʼs senile dementia with a neurofilament antiserum (1987) (14)
Light at the End of the Amyloid TunnelPublished as part of the Biochemistry series "Biochemistry to Bedside". (2018) (13)
High molecular weight microtubule‐associated proteins: Purification by electro‐elution and amino acid compositions (1986) (13)
Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase (2019) (13)
β-secretase inhibitors for Alzheimer's disease: heading in the wrong direction? (2019) (13)
Upregulation of Cellular Palmitoylation Mitigates α‐Synuclein Accumulation and Neurotoxicity (2020) (13)
Pink 1 Parkinson mutations , the Cdc 37 / Hsp 90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink 1 (2008) (13)
Proteolysis of chimeric beta-amyloid precursor proteins containing the Notch transmembrane domain yields amyloid beta-like peptides. (2002) (12)
The AMY antigen co-occurs with abeta and follows its deposition in the amyloid plaques of Alzheimer's disease and down syndrome. (1999) (12)
Wild-type GBA1 increases the α-synuclein tetramer–monomer ratio, reduces lipid-rich aggregates, and attenuates motor and cognitive deficits in mice (2021) (12)
Introducing transglutaminase into the study of Alzheimer's disease. A personal look back (2002) (12)
Altered conformation of α-synuclein drives dysfunction of synaptic vesicles in a synaptosomal model of Parkinson’s disease (2021) (12)
Soluble Aβ Oligomers Impair Dipolar Heterodendritic Plasticity by Activation of mGluR in the Hippocampal CA1 Region (2018) (12)
P4-209: Direct and potent regulation of γ-secretase by its lipid microenvironment (2008) (11)
Alzheimer's amyloid of another flavour (1995) (11)
Alpha 1-antichymotrypsin is present together with the beta-protein in monkey brain amyloid deposits. (1989) (11)
γ-Secretase: A Horseshoe Structure Brings Good Luck (2014) (10)
Synaptic plasticity and the mechanism of Alzheimer's disease (2008) (10)
Erratum: Folding proteins in fatal ways (2004) (10)
Identification of the Aβ37/42 peptide ratio in CSF as an improved Aβ biomarker for Alzheimer's disease (2022) (10)
Amyloid precursor on the Go (1993) (10)
Caspase-1 clipping causes complications for α-synuclein (2016) (9)
Molecular relation of amyloid filaments and paired helical filaments in Alzheimer's disease. (1990) (9)
Corrigendum: Resolving controversies on the path to Alzheimer's therapeutics (2011) (9)
Detection of soluble forms of the beta-amyloid precursor protein in human plasma. (1990) (9)
Amyloid-lowering isocoumarins are not direct inhibitors of gamma-secretase. (2002) (9)
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease (2022) (9)
Nomenclature of amyloid fibril proteins. Report from the meeting of the98. Part 1 [editorial] (1999) (9)
Antibodies to amyloid beta protein (A beta) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH). (1996) (9)
Rapid Alpha-Synuclein Toxicity in a Neural Cell Model and Its Rescue by a Stearoyl-CoA Desaturase Inhibitor (2020) (9)
Neuronal Loss of the Glutamate Transporter GLT-1 Promotes Excitotoxic Injury in the Hippocampus (2021) (9)
Toward structural elucidation of the γ-secretase complex (2009) (8)
Age‐Related Modifications of MAP‐2 (1986) (8)
Amyloid-like (Congophilic) neurofibrillary tangles do not react with neurofilament antisera in Alzheimer's cerebral cortex (2004) (8)
Bartels & Selkoe reply (2013) (8)
Massachusetts Alzheimer's Disease Research Center: Progress and challenges (2015) (7)
Alzheimer's disease. A technical KO of amyloid-beta peptide. (1998) (7)
Soluble derivatives of the beta amyloid protein precursor of Alzheimer's disease are labeled by antisera to the beta amyloid protein. (1989) (7)
Title Heparin-binding properties of the amyloidogenic peptides Aβ and amylin : Dependence on aggregation state and inhibition by Congo red Permalink (1997) (7)
Embryonic mosaic deletion of APP results in displaced Reelin-expressing cells in the cerebral cortex. (2017) (7)
Non-denaturing purification of alpha-Synuclein from erythrocytes (2011) (7)
42 NEUROFIBRILLARY DEGENERATION IN CHOLINERGIC AND NON-CHOLINERGIC NEURONS OF THE BASAL FOREBRAIN IN ALZHEIMERʼS DISEASE (AD) (1984) (7)
Polarized secretion of .3-amyloid precursor protein and amyloid (8-peptide in MDCK cells (7)
Alzheimer's disease. In the beginning... (1991) (7)
Relation Between Insulin, Insulin-related Factors, and Plasma Amyloid Beta Peptide Levels at Midlife in a Population-based Study (2012) (7)
Production and Characterization of Monoclonal Antibodies to Alzheimer Paired Helical Filaments (1985) (7)
The Pathophysiology of Alzheimer’s Disease (2000) (7)
Amyloid p Protein Precursor and the Pathogenesis of Alzheimer's Disease Minireview (1989) (7)
92 DIFFERENTIAL REACTION OF ALZHEIMER NEUROFIBRILLARY TANGLES WITH ANTI-NEUROFILAMENT AND ANTI-PHF ANTIBODIES (1983) (6)
A β dimer-containing human cerebrospinal fluid disrupts synaptic plasticity : prevention by systemic passive immunization (2009) (6)
DIFFUSE SENILE PLAQUES: THE CAUDATE AND PUTAMEN AS A MODEL (1989) (6)
Giving Alzheimer's the Old One-Two (2010) (6)
Fluorescent Analogue of Batimastat Enables Imaging of α-Secretase in Living Cells. (2016) (6)
A Is for Amyloid (2019) (6)
Alzheimerʼs disease: immunoreactivity of neurofibrillary tangles with anti-neurofilament and anti-paired helical filament antibodies (1987) (6)
Lack of specific association of presenilin 1 (PS-1) protein with plaques and tangles in Alzheimer's disease (1998) (5)
Showing transmitters the door: synucleins accelerate vesicle release (2017) (5)
Part 2. Notch-sparing γ-secretase inhibitors: The study of novel γ-amino naphthyl alcohols. (2016) (5)
Pathogenic Mechanisms of Cytosolic and Membrane-Enriched α-Synuclein Converge on Fatty Acid Homeostasis (2022) (5)
Evidence that α -Synuclein Does Not Inhibit Phospholipase D † (2009) (5)
Alzheimer's disease : new insights into an emerging epidemic (1992) (5)
TAU-SPECIFIC MONOCLONAL AND POLYCLONAL ANTIBODIES SUGGEST THAT TAU IS A MAJOR ANTIGENIC COMPONENT OF ALZHEIMER NEUROFIBRILLARY TANGLES (NFT) (1986) (5)
The search for an amyloid solution - Response (2002) (5)
Alzheimer's disease beyond 1994: The path to therapeutics (1994) (5)
Munchausen Syndrome—SLE (1970) (4)
TAU PROTEIN IS INTEGRATED INTO PAIRED HELICAL FILAMENTS (PHF) IN ALZHEIMERʼS DISEASE (AD) (1986) (4)
O2-02-02: Soluble amyloid β-protein dimers isolated directly from Alzheimer's disease patients potently impair synaptic plasticity and memory (2008) (4)
Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid (2001) (4)
Abundant Aβ fibrils in ultracentrifugal supernatants of aqueous extracts from Alzheimer’s disease brains (2022) (4)
A calcium-sensitive antibody isolates soluble amyloid-β aggregates and fibrils from Alzheimer’s disease brain (2022) (4)
Amyloid ß-Protein Deposition as a Seminal Pathogenetic Event in Alzheimer’s Disease (1991) (4)
Verubecestat for Prodromal Alzheimer's Disease. (2019) (4)
Chapter 67 – Alzheimer Disease (2015) (4)
Functional analysis and purification of a Pen‐2 fusion protein for γ‐secretase structural studies (2014) (4)
Physiological Production and Polarized Secretion of the Amyloid β-Peptide in Epithelial Cells: A Route to the Mechanism of Alzheimer’s Disease (1995) (4)
Plasma beta-amyloid level, cognitive reserve, and cognitive decline. (2011) (4)
New insights on the composition of neurofilaments. (1979) (4)
105 ANTIBODIES TO THE FAIL TO REACT WITH NEUROFILAMENTS AND OTHER NORMAL PROTEINS (1983) (4)
THE AMYLOID-B GENERATING TRI-PEPTIDE CLEAVAGE MECHANISM OF GAMMA-SECRETASE: IMPLICATIONS FOR ALZHEIMER'S DISEASE (2016) (3)
Nucleotide dependence of successive cycles of tubulin assembly (1979) (3)
P32 Phase III studies of crenezumab in early (prodromal-to-mild) Alzheimers disease (CREAD/CREAD2): Biomarker results (2020) (3)
DETECTION OF CIRCULATING FORMS OF THE β-AMYLOID PRECURSOR PROTEIN (BAPP) IN HUMAN PLASMA: 230 (1989) (3)
Protein homeostasis : a subject collection from Cold Spring Harbor Perspectives in biology (2012) (3)
The Impact of Novel Treatments on A\03B2 Burden in Alzheimer's Disease: Insights From a Mathematical Model (2015) (3)
Part 1: Notch-sparing γ-secretase inhibitors: The identification of novel naphthyl and benzofuranyl amide analogs. (2016) (3)
Ubiquitination of a Novel form of α-Synuclein by Parkin (2002) (3)
Substitution of phenylalanine by proline at position 19 of amyloid β peptide results in an increased production of amyloid β peptides with alternative N-termini after protein kinase C stimulation (1996) (3)
149 The Presenilin 1 and 2 mutations linked to familial Alzheimer's Disease increase the extracellular concentration of amyloid 0 protein (Aβ) ending at Aβ42(43) (1996) (3)
A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid (2015) (3)
Mechanisms of Aβ Production and Aβ Degradation: Routes to the Treatment of Alzheimer's Disease (2002) (3)
Alzheimer's disease: Conversation with an expert. (2002) (3)
Unfairness to Patients With Alzheimer Disease in Medicare's Coverage of Antiamyloid Immunotherapy. (2022) (3)
The role of T cell reactivity to A-beta amyloid peptide in the pathogenic processes associated with Alzheimer's disease (2000) (3)
Part 3: Notch-sparing γ-secretase inhibitors: SAR studies of 2-substituted aminopyridopyrimidinones. (2016) (3)
A novel V272D presenilin mutation associated with logopenia, disorientation, and apraxia in an autosomal-dominant Alzheimer's disease family (2020) (3)
Editorial overview: Neurobiology of disease (2016) (3)
TARGET ENGAGEMENT IN AN AD TRIAL: CRENEZUMAB LOWERS Aβ OLIGOMER LEVELS IN CSF (2018) (3)
Protein Chemical and Molecular Biological Studies of Amyloid Precursor Proteins in Alzheimer’s Disease (1988) (3)
ANTIBODIES TO DISTINCT REGIONS OF β-AMYLOID PRECURSOR PROTEIN (βAPP) DIFFERENTIALLY LABEL ALZHEIMER DISEASE (AD) SENILE PLAQUES: 88 (1989) (3)
By the way, doctor. Is there a brain scan that can specifically diagnose Alzheimer's disease? (2005) (2)
Microtubule-associated protein 2: monoclonal antibodies demonstrate the selective incorporation of certain epitopes into Alzheimer neurofibrillary tangles (1987) (2)
Nicastrin functions as a molecular gatekeeper to a high-affinity γ-secretase-substrate interaction driven by substrate transmembrane domain (2015) (2)
Peroxisome Proliferator-Activated Receptor Gamma Enhances the Activity of an Insulin Degrading Enzyme-Like Metalloprotease for Amyloid-β Clearance (2010) (2)
The Living Brain and Alzheimer’s Disease (2004) (2)
P1-230 Natural, cell-derived Aβ oligomers: their production, biological activity and inhibition (2004) (2)
150 Expression of the Presenilin proteins PS-1 and PS-2 in tissue culture cells (1996) (2)
388 Phosphorylation of ß-amyloid precursor protein at two distinct cellular locations (1996) (2)
Ten-year change in plasma amyloid β levels and late-life cognitive decline (2009) (2)
Biochemical and Structural Studies of Paired Helical Filaments and Senile Plaque Amyloid in Alzheimer’s Disease (1986) (2)
Biochemical and Structural Studies of Paired Helical Filaments and Senile Plaque Amyloid in Alzheimer’s Disease (1986) (2)
Parkinson-causing mutations in LRRK2 impair the physiological tetramerization of endogenous α-synuclein in human neurons (2022) (2)
Excess membrane binding of monomeric alpha-, beta- and gamma-synuclein is invariably associated with inclusion formation and toxicity (2021) (2)
Immunization Against Alzheimer’s Disease and Other Neurodegenerative Disorders (2003) (2)
Alzheimer's disease. Missense on the membrane. (1995) (2)
STUDIES OF THE PROCESSING OF β-AMYLOID PRECURSOR PROTEIN (βAPP) IN HUMAN, MONKEY AND RODENT BRAIN AND IN cDNA-TRANSFECTED CELLS: 156 (1989) (2)
PRODUCTION OF AMYLOID-SPECIFIC ANTIBODIES TO LOW MOLECULAR WEIGHT PROTEINS ISOLATED FROM ALZHEIMERʼS DISEASE (AD) BRAIN (1986) (2)
X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-(3 conformation (2)
Disease, transplantation and regeneration (1995) (2)
Interaction between parkin and alpha‐synuclein (2008) (2)
A CASE OF ALZHEIMER‐LIKE AMYLOID DEPOSITS WITHOUT ALZHEIMER'S DISEASE: 20 (1987) (2)
Report of Special Session on Bioassays and Standardization of Amyloid Proteins and Precursors (1991) (2)
68 Immunocytochemical characterization of plaques, tangles and vascular amyloid in the brains of 2 FAD patients with an identified psi mutation (1996) (2)
Enzymatic Assays for Studying Intramembrane Proteolysis. (2017) (2)
A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity (2022) (2)
Governing Coundl of the United Nations Development Programme (1985) (2)
Frontiers of Alzheimer research : proceedings of the 5th International Symposium of the Psychiatric Research Institute of Tokyo (PRIT), Tokyo, 10-12 September 1990 (1991) (2)
ISOLATION AND CHARACTERIZATION OF CEREBROVASCULAR AMYLOID (CVA) PROTEINS IN ALZHEIMER'S DISEASE: 192 (1987) (2)
146 Amyloidosis of Aβ42 as the common pathogenetic mechanism of all forms of Alzheimer's Disease (1996) (1)
P1-218 Generation of the intracellular C-terminal domain of the APP family of proteins does not require β-secretase (2004) (1)
Differential effect of agents altering vesicular pH on the generation of amyloid beta-peptide derived from mutant or wild type beta-APP (1994) (1)
Discovery of aryl aminothiazole γ-secretase modulators with novel effects on amyloid β-peptide production (2021) (1)
Nasal Aβ immunization reduces amyloid-β protein burden in PDAPP mice (2000) (1)
Corrigendum: Resolving controversies on the path to Alzheimer's therapeutics (2011) (1)
Clinical genetics, III: Alzheimer's disease: From genes to pathogenesis (1997) (1)
Lipase regulation of cellular fatty acid homeostasis as a Parkinson’s disease therapeutic strategy (2022) (1)
Roles in Alzheimer Disease Apolipoprotein E and Apolipoprotein E Receptors : Normal Biology and Subject Collection The Biology of Alzheimer Disease Animal Models of Alzheimer Disease (2012) (1)
Possible modifications of vimentin following acquisition of triton insolubility. (1984) (1)
Intraneuronal and Extracellular Filaments in the Pathogenesis of Alzheimer’s Disease (1987) (1)
Dynamic physiological α-synuclein S129 phosphorylation is driven by neuronal activity (2023) (1)
Structural Proteins in Alzheimer’s Disease (1986) (1)
Correction to: A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity (2022) (1)
Fluorescent Analogue of Batimastat Enables Imaging of alpha-Secretase in Living Cells (2016) (1)
DIFFERENT IMMUNOREACTTVITIES OF SYNTHETIC AND “NATIVE” β-AMYLOID PROTEIN (βAP) ANTISERA: 16 (1990) (1)
On the cutting edge of Alzheimer's disease therapy (2002) (1)
John Hardy Problems on the Road to Therapeutics The Amyloid Hypothesis of Alzheimer ' s Disease : Progress and (2011) (1)
EXTRACEREBRAL DEPOSITION OF ??-AMYLOID PROTEIN (??AP) IN ALZHEIMER??S DISEASE: 144 (1990) (1)
Molecular Properties of Paired Helical Filaments and Senile Plaque Amyloid Fibers in Alzheimer’s Disease (1986) (1)
DETECTION AND CHARACTERIZATION OF THE β‐AMYLOID PRECURSOR PROTEIN IN NEURAL AND NON‐NEURAL TISSUES AND CULTURED CELLS (1988) (1)
Colocalization of Parkin with α-Synuclein in the Lewy Bodies of Parkinson Disease (2002) (1)
BIOCHEMICAL ANALYSES OF SENILE PLAQUE AMYLOID CORES PURIFIED BY FLUORESCENCE ACTIVATED CELL SORTING (1985) (1)
Abstracts of the 15th Annual Meeting of the Israel Society for Neuroscience Eilat, Israel, December 3–5, 2006 (2006) (1)
Abstracts of the 15th Annual Meeting of the Israel Society for Neuroscience Eilat, Israel, December 3–5, 2006 (2006) (1)
Unraveling the Molecular Basis of Alzheimer's Disease Yields Novel Therapies: A Personal Retrospective (2009) (1)
Naturally assembled Abeta oligomers produce cognitive deficits (2003) (1)
762 Aβ is transported on lipoproteins and albumin in human biological fluids (1996) (1)
Predicting development of AD clinical symptoms and their progression through a collection of novel plasma Aβ immunoassays (2020) (1)
Molecular studies of the β-amyloid precursor protein. Its role in the pathogenesis of Alzheimer's disease (1989) (1)
Comprar Synaptic Plasticity and the Mechanism of Alzheimer's Disease | Selkoe, Dennis J. | 9783540763291 | Springer (2008) (1)
Title Effects of the amyloid precursor protein Glu 693 → Gln ' Dutch ' mutation on the production and stability of amyloid β-protein Permalink (1999) (1)
Generation and application of semi-synthetic p-Tau181 calibrator for immunoassay calibration. (2022) (1)
United Nations Framework Convention on Climate Change (1992) (1)
IMMUNOCYTOCHEMICAL STUDIES OF NEUROFIBRILLARY TANGLES IN AN AGED BEAR: 9 (1987) (1)
Disease-related protein changes in purified neurons from Alzheimer's and Huntington's diseases. (1979) (1)
News story miscasts Alzheimer’s science (2022) (1)
The Fibrous Proteins of Brain: A Primer for Gerontologists (1977) (1)
Enriched environment enhances β‐adrenergic signaling to prevent microglia inflammation by amyloid‐β (2023) (1)
CROSSLINKING OF ALZHEIMER PAIRED HELICAL FILAMENTS: ANALOGIES TO TRANSGLUTAM-INASE-CATALYZED FILAMENT CROSSLINKING IN VITRO (1982) (1)
161 MONOCLONAL ANTIBODIES TO ALZHEIMER PAIRED HELICAL FILAMENTS PRODUCED BY RAT-MOUSE HYBRIDOMAS (1984) (1)
Nigral Dopamine Neurons Endogenous Calcium Buffering Capacity of Substantia (2015) (0)
IC-101-05 fMRI alterations in medial temporal and default mode activity in MCI and AD (2006) (0)
697 Degradation of amyloid β-protein by a secreted metallo-protease in neural and non-neural cells (1996) (0)
ADRENOCORTICOTROPIC HORMONE- AND α-MELANOCYTE-STIMULATING HORMONE-LIKE IMMUNO-REACTIVE NEURITES IN SENILE PLAQUES (1986) (0)
Normal Production of the Amyloid β-Protein and the Pathogenesis of Alzheimer’s Disease (1995) (0)
A HEAD-TO-HEAD COMPARISON OF LEAD CLINICAL ANTI-Aβ ANTIBODIES (2018) (0)
CEREBELLAR PLAQUES IN PRESENILE DEMENTIA: GERSTMANN‐STRAUSSLER SYNDROME OR ALZHEIMER'S DISEASE? 19 (1987) (0)
Conservation of Microvascular and Senile Plaque Amyloid Proteins in Aged Mammals and in Humans with Alzheimer's Disease (AD) (1987) (0)
Studies on the Relationship between Plasma Proteins and Amyloid Fibrils Found in Alzheimer's Disease (1988) (0)
CHARACTERIZATION OF SOLUBLE TRUNCATED FORMS OF THE AMYLOID PRECURSOR PROTEIN FROM HUMAN PLASMA: 148 (1990) (0)
Insulin degrading enzyme (IDE): implications for the degradation and neurotoxicity of the amyloid β-protein (2000) (0)
Supplemental Information Crucial Roles for SIRT 2 and AMPA Receptor Acetylation in Synaptic Plasticity and Memory (2017) (0)
Use it or lose it: environmental novelty, β2-adrenergic signaling, and the prevention of oAβ toxicity (2014) (0)
P4-189 Identification of a novel translational isoform of insulin-degrading enzyme (2004) (0)
Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer’s disease (2018) (0)
Book Received (1962) (0)
Amyloid precursor protein expression and β-amyloid release in fibroblast cell lines obtained from family members with the Swedish APP670/671 mutation (1994) (0)
Toward the Identification of γ‐Secretase: Using Transition State Analog Inhibitors (2002) (0)
O1-05-01 (2006) (0)
Author's response to commentaries (1989) (0)
Presenilins, APP, and Notch: Proteolysis from Womb to Tomb (2002) (0)
Procedures for the identification of inhibitors of the production of the beta amyloid peptide. (1993) (0)
Toward a phenome-wide view of Parkinson's disease (2022) (0)
AlterationsinMemoryNetworksinMildCognitive ImpairmentandAlzheimer'sDisease:AnIndependent ComponentAnalysis (2006) (0)
Role of Disrupted-in-Schizophrenia-1 (DISC1) in amyloid precursor protein (APP) processing and Aβ generation (2010) (0)
O4-06-06 Endogenous neprilysin modulates cerebral Aβ levels, amyloid plaque burden, and amyloid angiopathy in human APP transgenic mice (2006) (0)
Human αsynuclein exists in both monomeric and polymeric membrane-bound forms in transgenic mice and MES23.5 dopaminergic cells overexpressing WT and A53T mutant αsynuclein (2000) (0)
to changed its screening of compounds for their ability to production of beta-amyloid peptides (1997) (0)
The Notch transmembrane domain can be cleaved by γ-secretase (2000) (0)
Mechanistic Studies of the Effect of Presenilins 1 and 2 on APP Metabolism (1998) (0)
A NOVEL CELLULAR COMPLEX OF BACE1 AND γ-SECRETASE SEQUENTIALLY GENERATES Aβ FROM APP (2019) (0)
Tau Immunostaining in Alzheimer's Disease and Other Neurodegenerative Disorders (1987) (0)
A method for identifying inhibitor compounds for the release of beta-amyloid peptide (BAP) (1993) (0)
O4-02-04 Opposing roles of APP and Abeta on synaptic plasticity (2006) (0)
The Complex Pathways to Mechanism-Based Therapeutics in Alzheimer’s Disease (2016) (0)
An oligomer‐directed Aβ antibody decreases synaptotoxic oligomeric Aβ in brain and improves behavioral abnormality in humanized APP knock‐in mice (2022) (0)
Intranasal Aβ Vaccination as an Approach to Treating β-Amyloidosis (2003) (0)
A NOVEL PARADIGM FOR THE IDENTIFICATION AND TARGETING OF BIOACTIVE ABETA SPECIES FROM ALZHEIMER BRAIN (2016) (0)
S4-01-01: Presenilin/gamma-secretase: Electron microscopic structure and regulation by cholesterol and membrane lipids (2008) (0)
Multiple Levels of Synaptic Regulation by NMDA-type Glutamate Receptor in Normal and Disease States (2008) (0)
Candidate-based search for Amyloid Precursor Protein ligands that modulate α-secretase cleavage (2011) (0)
COMPONENT OF THE AMYLOID DEPOSITS IN ALZHEIMER'S DISEASE (1988) (0)
Correction. Study of an octadecaneuropeptide derived from diazepam binding inhibitor (DBI): biological activity and presence in rat brain. (1986) (0)
Toward identification of gamma-secretase using transition-state analogue inhibitors (2000) (0)
TREATING ALZHEIMER’S DISEASE BY TARGETING β-AMYLOID: WHERE DO WE STAND? (2017) (0)
Cell-derived Aβ oligomers: production, activity and inhibition (2002) (0)
Evaluation of [N-2-fluoropropyl]-2-(4'(methylamino)phenyl)-6-hydroxybenzothiazole as a potential A{beta} amyloid polymerization inhibitor and PET tracer (2010) (0)
Intraneuronal Beta-Amyloid Accumulation is Associated With MAP2 and Tau Microtubule Pathology (2007) (0)
Plasma levels of an N‐terminal tau fragment predict core AD and neurodegenerative biomarkers in autosomal dominant Alzheimer’s disease: Findings from DIAN (2022) (0)
Secreted 1-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances Xs phosphorylation (0)
P2-268 Amyloid deposition in presymptomatic familial Alzheimer’s disease (2006) (0)
Reply (1989) (0)
INCREASED RATE OF ACCUMULATION OF CHAT PROXIMAL TO A SCIATIC NERVE LIGATURE IN A13+-TREATED RABBITS: 61 (1982) (0)
Biology and genetics of the presenilin proteins associated with alzheimer disease (1997) (0)
Plasma Biomarkers of Neurodegeneration and Tau in Relation to Longitudinal Depressive Symptoms in Older Adults: Findings from the Harvard Aging Brain Study (2022) (0)
The Parkinson-Causing LRRK2 Mutation G2019S Impairs the Physiological Tetramerization of Α-Synuclein in Human Neurons (2021) (0)
The relation between insulin, insulin-related factors, and plasma amyloid-beta protein levels at mid-life in a large-scale population-based study (2010) (0)
Human iPSC-derived neurons reveal novel effects of the APP London mutation and show cell fate-specific Alzheimer’s disease relevant phenotypes (2013) (0)
P3.085 Novel bio-panning technique to isolate scFv against low concentrations of toxic natural brain derived Abeta oligomers (2009) (0)
O4-03-04 Reversal of AB induced LTP deficits by compounds that inhibit AB oligomerization (2004) (0)
Plasma NT1-tau and AÎ²42 correlate with age and cognitive function in two large Down syndrome cohorts (2023) (0)
An in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimer’s disease (2018) (0)
Synthesis and evaluation of a series of scyllo-inositol/2-(fluoroethyl)-8-methyl-2,8-diazaspiro[4,5]decane-1,3-dione combined derivatives as potential amyloid-beta polymerization inhibitors and PET oligomer-Abeta probes (2010) (0)
Familial hyperprolinemia and mental retardation (1969) (0)
Increased expression of , 8-amyloid precursor protein during neuronal differentiation is not accompanied by secretory cleavage ( Alzbeimer disease / brain development / membrane proteins / neurofilament / tubulin ) (2004) (0)
RECOGNITION OF SENILE PLAQUE & MICROVASCULAR AMYLOID IN AGED ANIMALS BY ANTIBODIES TO AMYLOID PROTEINS IN ALZHEIMER'S DISEASE (AD): 190 (1987) (0)
O1-05-01 Cortical amyloid deposition related to failure of hippocampal activation (2007) (0)
Aging Brain , Aging Mind Late in life the human brain suffers attrition of certain neurons and undergoes chemical alterations (0)
Non‐denaturing affinity purification of soluble oligomeric Aβ from human brain using a novel calcium‐sensitive monoclonal antibody (2021) (0)
Adverse Neurologic Effect of BACE1 inhibitors in Alzheimer’s disease trials (2020) (0)
Probes for the Molecular Components of Plaques and Tangles Point to a Broadening View of Alzheimer Pathology (1989) (0)
P1-391 Monomeric Aβ peptides bearing the Flemish A21G mutation are less readily degraded by neprilysin than wild type Aβ (2006) (0)
Altered Conformation of α-Synuclein Drives Malfunction of Synaptic Vesicles in a Model of Parkinson's Disease (2020) (0)
690 Characterization of the amyloidogenic subunits Aß1–40. Aβ1–42, Aβ1–40 (Dutch) and amylin: heparin-binding properties and multiple effects of Congo red (1996) (0)
P3-352 APLP1-derived peptides do not undergo rapid fibrillogenesis (2006) (0)
γ-Secretase inhibitors which have been shown to block Aβ production do not abolish Notch1 signaling (2000) (0)
Apolipoprotein E and Alzheimer’s Disease (1996) (0)
Aβ oligomers from human brain impair mossy fiber LTP in CA3 of hippocampus, but activating cAMP-PKA and cGMP-PKG prevents this (2022) (0)
Alzheimer's and Parkinson's disease: anatomical, pathological and biochemical aspects (1986) (0)
A de novo designed α-helical peptide forms amyloid fibrils which are not neurotoxic (2000) (0)
Cell Biology of Amyloidogenesis: An overview (2002) (0)
System in Alzheimer Disease Lysosomal - Proteasome System and the Autophagic - The Ubiquitin (2012) (0)
Short Communication Microin jection ofSynthetic Amyloid (3-Protein in MonkeyCerebral Cortex Fails toProduce Acute Neurotoxicity (1993) (0)
Molecular basis of presenilin's role in APP processing (2000) (0)
Amyloid imaging with PIB associated with impaired memory function on fMRI (2007) (0)
The seventh age of man: Solving senility (2006) (0)
Author's response to commentaries (1986) (0)
Alzheimer's disease. Amyloid precursor on the G(o) (1993) (0)
P3-415: The presence of Abeta dimers in soluble brain extract is associated with dementia (2008) (0)
Biochemical and Molecular Studies of Native and Synthetic B-Amyloid Protein in Alzheimer’s Disease (1988) (0)
Ready for prime time (2012) (0)
PROTEOLYTIC PROCESSING OF THE β-AMYLOID PRECURSOR PROTEIN (1998) (0)
Molecular biology and genetics of Alzheimer's disease : proceedings of the International Symposium on Dementia : Molecular Biology and Genetics of Alzheimer's Disease, Niigata, Japan, 11-14 November 1989 (1990) (0)
Comparison of amyloid from Alzheimer’s disease with synthetic peptide (1988) (0)
Cellular production of amyloid beta-protein: a direct route to the mechanism and treatment of Alzheimer's disease (1994) (0)
Genetic Animal Models for Brain Diseases (2011) (0)
COMPLETE HOMOLOGY OF AMYLOID PRECURSOR PROTEIN (APP) IN MONKEY AND HUMAN SUPPORTS A PRIMATE MODEL OF β-AMYLOIDOSIS: 143 (1990) (0)
Lipase regulation of cellular fatty acid homeostasis as a Parkinson’s disease therapeutic strategy (2022) (0)
PERICAPILLARY AMYLOID IN ALZHEIMER??S DISEASE (AD): 23 (1990) (0)
Intraneuronal Aβ42 immunoreactivity is inversely correlated with Alzheimer's disease pathology in down syndrome brain: A temporal study (2000) (0)
P4-318 Step-wise assembly of γ-secretase: presenilin holoprotein binds to the nicastrin-APH-1 subcomplex prior to the addition of PEN-2 (2004) (0)
Moving beyond amyloid and tau to capture the biological heterogeneity of Alzheimer’s disease (2023) (0)
Localization of complexes of presenilin and the APP C-terminal fragments C83 and C99 to the subcellular sites of Aβgeneration (2000) (0)
HPLC Analysis of Proteins from Alzheimer Paired Helical Filaments (1987) (0)
S1-02-04 Role of AB oligomers in AD (2006) (0)
α1-ANTICHYMOTRYPSIN IN BRAIN AGING AND DISEASE (1988) (0)
Aqueously diffusible RNA-bound amyloid-β aggregates in Alzheimer disease brain (P1-6.004) (2023) (0)
Editorial Board (2007) (0)
P3-326: Neprilysin regulates the anatomical distribution of amyloid pathology in an age-dependent manner (2008) (0)
In Vitro Production of Amyloid β-Protein: A Route to the Mechanism and Treatment of Alzheimer’s Disease (1994) (0)
Alzheimer's Disease in Twins (1981) (0)
Editorial Board (2011) (0)
Disease, transplantation and regeneration (1995) (0)
320 Effect of presenilin mutations on BAPP processing in presenilin transfected cells (1996) (0)
Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase (2020) (0)
Role of presenilin in APP processing and Aβ production (2001) (0)
Learnings about Aβ from human brain recommend the use of a live-neuron bioassay for the discovery of next generation Alzheimer’s disease immunotherapeutics (2023) (0)
Palmitoylation of the Parkinson’s disease–associated protein synaptotagmin-11 links its turnover to α-synuclein homeostasis (2023) (0)
IC-103-03 Amyloid deposition in presymptomatic familial Alzheimer’s disease (2006) (0)
S2-03-01 Presenilin as the active site of gamma-secretase, a novel intramembranous aspartyl protease (2004) (0)
Method of identifying inhibitors of beta amyloid peptide production (1993) (0)
Symposium The molecular basis of Alzheimers disease (1997) (0)
A Substrate-Based Difluoro Ketone Selectively Inhibits Alzheimer′s γ-Secretase Activity. (1998) (0)
Treatment of Alzheimer’s disease by modulation of microglial neuroinflammation by nasal anti‐CD3 mAb (2022) (0)
O4-05-08 In utero gene transfer reveals a function for APP in cortical cell migration (2006) (0)
Secreted amyloid beta and impaired neurotrophin transport: Potential mediators of abnormal cns development and neurodegeneration in down syndrome (2010) (0)
News briefs (1992) (0)
P2-302 FMRI alterations medial temporal and neocortical networks in MCI and AD (2006) (0)
(hydroxyethyl)urees utilisees en tant qu'inhibiteurs de la production de beta-amyloide de la maladie d'alhzeimer (2001) (0)
Alzheimer's drugs: Does reducing amyloid work?-Response. (2021) (0)
The Aging Mind: Deciphering Alzheimer's Disease & its Antecedents (2006) (0)
The Parkinson-associated toxin paraquat shifts physiological αS tetramers toward monomers that can be calpain-truncated and form oligomers. (2023) (0)
Transcriptomic correlates of neurite degeneration due to human brain‐derived Aβ and protection by clinical anti‐Aβ antibodies (2020) (0)
Molecular Calcium and Vesicle Recruitment at the Calyx of Held (2007) (0)
P1-368: Monomeric and oligmeric Aβ assays on plasma of Alzheimer patients (2008) (0)
ADF/cofilin-actin rods and synaptic loss in Alzheimer's disease (2010) (0)
Table of Contents (1994) (0)
CRIBLAGE DE COMPOSES CAPABLES DE MODIFIER LA PRODUCTION DE PEPTIDE AMYLOIDE-β (x-≥41) (1997) (0)
Studies of the Beta-Amyloid Precursor Protein in Brain and the Pathological Transformation of Tau into the Neurofibrillary Tangle (1988) (0)
Plasma levels of an N‐terminal tau fragment are highly associated with future cognitive decline and neurodegeneration in clinically normal elderly (2020) (0)

This paper list is powered by the following services:

Other Resources About Dennis J. Selkoe

en.wikipedia.org

What Schools Are Affiliated With Dennis J. Selkoe?

Dennis J. Selkoe is affiliated with the following schools:

Dennis J. Selkoe's Academic­Influence.com Rankings